What future do digital therapeutics have, and what potential can they offer in the near future?
The digitalization of wellness and health products has exploded in recent years. It provided new means that might allow tackling various health-related issues. Also, they help to find approachable alternatives to offer people a better chance to attain well-being.
But what future do the digital health platforms have, and what potential can they offer in the near future?
For starters, let’s begin by defining what digital health is.
Digital health is like an umbrella term that consists of several types of software platforms. It comprises devices, wearables and sensors, health data technology, personalized medicine, and digital therapeutics (DTx).
The most promising field of digital health is its subsection DTx. It contains multiple technologies and services that can aid healthcare and wellness industries.
DTx has a unique capability to commit clinically proven therapeutic interventions to prevent, manage, or treat medical disorders or diseases. Digital therapeutics provide an additional help alongside traditional treatment of health conditions. Also, it can be a replacement for conventional pharmaceuticals in general.
In recent years, the DTx industry is growing fast and has the potential to replace some traditional therapeutics. For example, DTx-based mobile apps and devices can help patients manage their medical conditions. These apps remind them about dosage time, making medication adherence more comfortable. It can also guide users in reaching a healthy lifestyle, managing diseases like diabetes, or aiding those with chronic disorders like PTSD.
DTx progress and the ability to cover more health-related concerns have a lot to do with recent technological advancements. Nowadays, there’s a chance of producing these devices and software platforms at optimal speed and quantity, making DTx more cost-effective than ever.
Despite the growing DTx industry, it has versatile ability in providing solutions to health problems and data confirming their clinical value. It faces some struggles in taking part in the healthcare mainstream. This industrial obstacle stems from two reasons.
First of all, it’s pretty challenging for consumers and medical professionals to distinguish apps in terms of which one has or doesn’t have a proven therapeutic value. That’s why in some countries like the US and Germany, institutions became responsibile for overseeing the accreditation. They check DTx platforms for their clinical validity and mark these products so that each medical specialist could recognize them.
Developers who want to sell their software and receive accreditation have to carry out trials, collect data, and follow other procedures.
There is another obstacle to solved on the road to the wide adoption of digital therapeutics. It is the misalignment of incentives among providers, payers, and pharmaceutical companies.
DTx asks healthcare providers to change their workflows. That would mean that specialists would have to learn how to adopt digital tools within their medical practice. There is a high chance that the payer will expect some reimbursement before getting a DTx as well.
Yet, the healthcare bureaucratic processes would need administrative adjustment in order to find enough cash to ensure compensation.
In that regard, pharmaceutical and insurance companies will demand from DTx developers to prove their platform’s effectiveness. Companies will have to back their claims up with comprehensive data. This process might take some precious time. However, collecting needed information about products’ benefits won’t 100% guarantee that healthcare-related institutions approved the app.
No matter these struggles, there’s a positive aspect behind these industrial obstacles as well. The shared interest in DTx has brought both pharmaceutical companies and software developers in one place. This fascination has created new opportunities to share know-how from both sides, potentially accelerating the development and adoption of DTx.
That being said, digital therapeutics (DTx) will soon become a new category of medicine.
It is capable of addressing all kinds of health conditions and helping people in need. Much work remains for developers and specialists working in the healthcare system in finding the best way to integrate DTx within the traditional medical ecosystem. Yet, by keeping up with the current pace and determination, DTx can become an indispensable part of medical practice.
If you want to find out more about digital therapeutics, check out Kasparas Aleknavičius’ presentation at the “Health for all 2021” conference here.
One of the first experiences Romy Carlson had after she joined Kilo Health was flying out to Lithuania, going to the National Opera and Ballet Theater, and listening to an orchestra during an event presenting the future of health. While…
Hiring processes can be draining. With all the stressful stages, it feels like one big interrogation. As much as we love crime documentaries on Netflix, we try to take a different approach and make the experience as smooth as possible….
Kilo Health became Europe’s second fastest-growing company twice already. At first, Deloitte ranked us among the tech leaders in Central Europe, and then the Financial Times named us the runner-up in Europe. Growth is at our core, and we got…